{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:43:58Z","timestamp":1790336638694,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41433-025-04030-7","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:02:26Z","timestamp":1759413746000},"page":"3129-3134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FYB-201 Biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) Efficacy and Safety in Clinical Settings \u2013 FORCE study"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8550-9791","authenticated-orcid":false,"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vazquez-Alfageme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasuki","family":"Sivagnanavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Fausto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Soare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Bautista","family":"Salamanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-9542","authenticated-orcid":false,"given":"Lorenzo","family":"Fabozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthi","family":"Tsika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Cejudo","family":"Corbalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Gomez","family":"Verdejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-6079","authenticated-orcid":false,"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-7169","authenticated-orcid":false,"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Kolomeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Retina Biosimilar Study Group (Inter BIOS Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemantini","family":"Ayachit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitaranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourous A.","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodjikian","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Holekemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Hilely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian W. M.","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"DO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil G.","family":"Falavarjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Zinkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"4030_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294.","journal-title":"BMC Ophthalmol"},{"key":"4030_CR2","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser PK, Schmitz-Valckenberg MS, Holz FG. anti-vascular endothelial growth factor biosimilars in ophthalmology. Retina. 2022;42:2243\u201350.","journal-title":"Retina"},{"key":"4030_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68:2143\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"4030_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","volume":"224","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for Retinal Diseases: An Update. Am J Ophthalmol. 2021;224:36\u201342.","journal-title":"Am J Ophthalmol"},{"key":"4030_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. 2023;23:851\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"4030_CR6","doi-asserted-by":"crossref","unstructured":"Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, et al. International Retina Biosimilar Study Group (Inter BIOS Group). Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (Lond). 2024;38:3392\u20135.","DOI":"10.1038\/s41433-024-03284-x"},{"key":"4030_CR7","unstructured":"FYB 201. https:\/\/www.formycon.com\/en\/biosimilars\/fyb201\/. Accessed March 17, 2025."},{"key":"4030_CR8","unstructured":"Prescribing information. https:\/\/www.cimerli.com\/pdf\/prescribing-information.pdf. Accessed March 17, 2025."},{"key":"4030_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: \u201cIs there a big change on the horizon?\u201d Clin Ophthalmol. 2018;12:2137\u201343.","journal-title":"Clin Ophthalmol"},{"key":"4030_CR10","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41433-019-0722-6","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye. 2020;34:1006\u20137.","journal-title":"Eye"},{"key":"4030_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ophtha.2021.09.008","volume":"129","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kuppermann BD. Biosimilars for Retinal Diseases: Understanding the Phase 3 Clinical Trial Design. Ophthalmology. 2022;129:65\u201366.","journal-title":"Ophthalmology"},{"key":"4030_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000488602","volume":"241","author":"S Sharma","year":"2019","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life clinical effectiveness of Razumab\u00ae (the world\u2019s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24\u201331.","journal-title":"Ophthalmologica"},{"key":"4030_CR13","first-page":"368","volume":"6","author":"S Sharma","year":"2018","unstructured":"Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab\u00ae (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration: a subgroup analysis of pooled retrospective RE-ENACT study. Int J Oph Thalmol Eye Res. 2018;6:368\u201373.","journal-title":"Int J Oph Thalmol Eye Res"},{"key":"4030_CR14","doi-asserted-by":"crossref","unstructured":"Sharma A, Holz FG, Kumar N, Sarraf D, Ayachit S, Mishra C et al. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. J Vitreoret Dis. 2025:24741264251322213.","DOI":"10.1177\/24741264251322213"},{"key":"4030_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101358","volume":"25","author":"A Sharma","year":"2022","unstructured":"Sharma A, Arunaprakash J, Das A, Nayaka A, Kumar N, Parachuri N, et al. Ranizurel safety evaluation in real-world -(RaSER) study. Am J Ophthalmol Case Rep. 2022;25:101358.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4030_CR16","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41433-024-03220-z","volume":"38","author":"T Ueda-Consolvo","year":"2024","unstructured":"Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, et al. Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study). Eye. 2024;38:3193\u20136.","journal-title":"Eye"},{"key":"4030_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1177\/24741264231202080","volume":"7","author":"A Sharma","year":"2023","unstructured":"Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases. J Vitreoretin Dis. 2023;7:474\u20136.","journal-title":"J Vitreoretin Dis"},{"key":"4030_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41433-022-02287-w","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kumar N, Parachuri N, Regillo C, Bandello F, Kuppermann BD. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?. Eye. 2023;37:1953\u20134.","journal-title":"Eye"},{"key":"4030_CR19","unstructured":"FDA. Considerations in demonstrating interchangeability with a reference product: Update. Updated June 20, 2024. Accessed March 17, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04030-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:28Z","timestamp":1763424268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04030-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04030-7","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Luke Nicholson- None. Clara Vazquez-Alfageme- None. Vasuki Sivagnanavel \u2013 None. Riccardo Fausto \u2013 None. Maria Cristina Soare \u2013 None. Marta Bautista Salamanca \u2013 None. Lorenzo Fabozzi- None. Chrysanthi Tsika- None. Olga Cejudo Corbalan \u2013 None. Alejandro Gomez Verdejo-None. Hana Mansour- None. Bita Momenaei \u2013 None. Taku Wakabayashi\n                      -\n                      None. Se Joon Woo\n                      -\n                      Dr Woo reported serving as a consultant for Samsung Bioepis and Panolos Bioscience; being cofounder of Retimark; serving as an advisory board member of Novartis and Novelty Nobility; receiving grants and personal fees from Samsung Bioepis, Novartis, Novelty Nobility, Alteogen, Kookje, and Curacle; and receiving lecture fees from Novartis, Bayer, Allergan, AbbVie, Alcon, Taejoon, SCAI Therapeutics, and Alteogen. Anton M Kolomeyer\n                      - -\n                      None. Carl D Regillo: Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Aviceda, Bausch and Lomb, Clearside, Cognition, EyePoint, Genentech, Iveric, Janssen, Kodiak, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Ocuphire, Opthea, Ray, RegenXBio, Stealth, Thea, Zeiss; Research grant support: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, Iveric, Janssen, Kodiak, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In this preliminary study conducted in clinical settings, the ranibizimab biosimilar (FYB 201) demonstrated efficacy across a range of vascular endothelial growth factor (VEGF)-driven macular disorders. The safety profile of the ranibizumab biosimilar (FYB 201) was observed to be comparable to that of the reference product (Lucentis, Genentech, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Synopsis\/Precis"}}]}}